OC
PCVX icon

Oppenheimer & Co’s Vaxcyte PCVX Stock Holding History

Oppenheimer & Co’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,459
Closed -$510K – 1628
2024
Q3 		$510K Buy
+4,459
New +$402K 0.01% 1026

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oppenheimer & Co's PCVX Position: Q4 2024 in Review

Oppenheimer & Co sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 4,459 shares — an estimated $510K sold.

Oppenheimer & Co first reported a position in PCVX in Q3 2024 and held it in 1 quarter. The position peaked at $510K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Oppenheimer & Co reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 4,459 Vaxcyte shares in Q4 2024, an estimated $510K.
  • Oppenheimer & Co first reported a position in Vaxcyte in Q3 2024 and held it in 1 quarter.
  • Oppenheimer & Co's Vaxcyte position peaked at $510K in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Oppenheimer & Co's 13F filing for Q4 2024, filed 5 Feb 2025.